Quality adjusted survival analysis
Abstract
We present a technique, quality adjusted survival analysis, for the analysis of controlled trials where patients may experience several health states which differ in their quality of life. When the data are censored, a survival analysis of the quality adjusted life years achieved may involve informative censoring, and produce biased estimates. To overcome this, we partition the survival curve; the resulting areas, which represent the mean time in each state, are multiplied by utility weights to provide an unbiased estimate of (restricted) quality adjusted survival.
If the appropriate weights are in doubt, the results are best presented as a threshold analysis over the utility weights, allowing individual recommendation to be read from a simple graph. The certainty of the conclusions can be presented as confidence bands on the threshold line. The techniques are illustrated with a re‐analysis of a large three‐arm trial of adjuvant chemoendocrine therapy for stage II breast cancer in post‐menopausal women. This shows that if the value of time spent in toxicity is greater than the time spent in relapse, we can be 95 per cent confident that chemoendocrine therapy is the preferred option.
Citing Literature
Number of times cited according to CrossRef: 197
- Hans Wildiers, Olivia Le Saux, Research Methods: Clinical Trials in Geriatric Oncology, Geriatric Oncology, 10.1007/978-3-319-57415-8, (1063-1076), (2020).
- Dennis Dobler, Andrew Titman, Dynamic inference for non‐Markov transition probabilities under random right censoring, Scandinavian Journal of Statistics, 10.1111/sjos.12443, 47, 2, (572-586), (2020).
- Chia-Hua Chung, Tsuey-Hwa Hu, Jung-Der Wang, Jing-Shiang Hwang, Estimation of Quality-Adjusted Life Expectancy of Oral Cancer Patients: Integration of Lifetime Survival With Repeated Quality-of-Life Measurements, Value in Health Regional Issues, 10.1016/j.vhri.2019.07.005, 21, (59-65), (2020).
- Mingjun Rui, Hongchao Li, Cost-effectiveness of Osimertinib vs Docetaxel-Bevacizumab in Third-Line Treatment in EGFR T790M Resistance Mutation Advanced Non–Small Cell Lung Cancer in China, Clinical Therapeutics, 10.1016/j.clinthera.2020.08.018, (2020).
- Joshua A. Roth, Josh J. Carlson, Fang Xia, Todd Williamson, Sean D. Sullivan, The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2020.20045, (1-6), (2020).
- Mingjun Rui, Fenghao Shi, Ye Shang, Rui Meng, Hongchao Li, Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model, Advances in Therapy, 10.1007/s12325-020-01418-7, (2020).
- Jeanny B. Aragon‐Ching, Ravi A. Madan, Life under the CABOSUN: Cabozantinib improves quality‐adjusted survival in comparison with sunitinib, Cancer, 10.1002/cncr.33168, 0, 0, (2020).
- Tianyu Zhan, Douglas E. Schaubel, Semiparametric regression methods for temporal processes subject to multiple sources of censoring, Canadian Journal of Statistics, 10.1002/cjs.11528, 48, 2, (222-237), (2019).
- Devin Incerti, Howard Thom, Gianluca Baio, Jeroen P. Jansen, R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment, Value in Health, 10.1016/j.jval.2019.01.003, 22, 5, (575-579), (2019).
- R. K. Kerridge, P. P. Glasziou, K. M. Hillman, The Use of “Quality-Adjusted Life Years” (QALYs) to Evaluate Treatment in Intensive Care, Anaesthesia and Intensive Care, 10.1177/0310057X9502300309, 23, 3, (322-331), (2019).
- Emmanuel Caruana, Yohann Foucher, Philippe Tessier, Jean-Sébastien Frenel, Jean-Marc Classe, Etienne Dantan, Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer, Breast Cancer Research and Treatment, 10.1007/s10549-018-05107-6, (2019).
- Kim Cocks, Marta Contente, Sarah Simpson, Michael DeRosa, Fiona C. Taylor, James W. Shaw, A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck, PharmacoEconomics, 10.1007/s40273-019-00798-1, (2019).
- Xiufang Liu, Dianliang Deng, Dehui Wang, Estimating the quantile medical cost under time-dependent covariates and right censored time-to-event variable based on a state process, Statistical Methods in Medical Research, 10.1177/0962280219882968, (096228021988296), (2019).
- Rohit Mistry, Jessica R. May, Gaurav Suri, Kate Young, Diana Brixner, Gary Oderda, Joseph Biskupiak, Derek Tang, Subrata Bhattacharyya, Dinesh Mishra, Devarshi Bhattacharyya, Anand A. Dalal, Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2018.24.6.514, 24, 6, (514-523), (2018).
- Kristina Lambrakis, John K. French, Ian A. Scott, Tom Briffa, David Brieger, Michael E. Farkouh, Harvey White, Anthony (Ming-Yu) Chuang, Kathryn Tiver, Stephen Quinn, Billingsley Kaambwa, Matthew Horsfall, Erin Morton, Derek P Chew, The appropriateness of coronary investigation in myocardial injury and Type 2 myocardial infarction (ACT-2): A randomized trial design, American Heart Journal, 10.1016/j.ahj.2018.09.016, (2018).
- Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner, Chee Khoon Lee, Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis, Therapeutic Advances in Medical Oncology, 10.1177/1758835918788500, 10, (175883591878850), (2018).
- Brian Claggett, Lu Tian, Haoda Fu, Scott D. Solomon, Lee‐Jen Wei, Quantifying the totality of treatment effect with multiple event‐time observations in the presence of a terminal event from a comparative clinical study, Statistics in Medicine, 10.1002/sim.7907, 37, 25, (3589-3598), (2018).
- Min Huang, M. Catherine Pietanza, Ayman Samkari, James Pellissier, Thomas Burke, Sheenu Chandwani, Fansen Kong, A. Simon Pickard, Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer, PharmacoEconomics, 10.1007/s40273-018-0752-0, (2018).
- Jaclyn Beca, Don Husereau, Kelvin K. W. Chan, Neil Hawkins, Jeffrey S. Hoch, Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment, PharmacoEconomics, 10.1007/s40273-017-0583-4, 36, 1, (7-15), (2017).
- P. Marino, P. Sfumato, F. Joly, K. Fizazi, S. Oudard, S. Culine, M. Habibian, J.-M. Boher, G. Gravis, Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial, European Journal of Cancer, 10.1016/j.ejca.2017.07.008, 84, (27-33), (2017).
- Cynthia Papendick, Andrew Blyth, Anil Seshadri, Michael J.R. Edmonds, Tom Briffa, Louise Cullen, Stephen Quinn, Jon Karnon, Anthony Chuang, Adam J. Nelson, Matthew Horsfall, Erin Morton, Derek P. Chew, A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: Design of the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T (RAPID-TnT) study, American Heart Journal, 10.1016/j.ahj.2017.05.004, 190, (25-33), (2017).
- Hans Wildiers, Olivia Le Saux, Research Methods: Clinical Trials in Geriatric Oncology, Geriatric Oncology, 10.1007/978-3-319-44870-1, (1-14), (2017).
- Josep Tabernero, Eric Van Cutsem, Atsushi Ohtsu, Nadia Amellal, Stéphanie Cadour, Ronan Fougeray, Benjamin Haffemayer, Robert J Mayer, QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer, ESMO Open, 10.1136/esmoopen-2017-000284, 2, 5, (e000284), (2017).
- Eric Van Cutsem, Alfredo Falcone, Rocio Garcia-Carbonero, Yoshito Komatsu, Alessandro Pastorino, Marc Peeters, Yasuhiro Shimada, Kentaro Yamazaki, Takayuki Yoshino, Alberto Zaniboni, Nadia Amellal, Akira Kanehisa, Robert Winkler, Lukas Makris, Robert J Mayer, Atsushi Ohtsu, Josep Tabernero, Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial, ESMO Open, 10.1136/esmoopen-2017-000261, 2, 5, (e000261), (2017).
- Brent A. Johnson, Nonparametric Two‐Sample Tests of the Marginal Mark Distribution with Censored Marks, Scandinavian Journal of Statistics, 10.1111/sjos.12265, 44, 2, (545-562), (2017).
- Yifei Sun, Mei-Cheng Wang, Evaluating Utility Measurement From Recurrent Marker Processes in the Presence of Competing Terminal Events, Journal of the American Statistical Association, 10.1080/01621459.2016.1166113, 112, 518, (745-756), (2017).
- Yifei Sun, Chiung-Yu Huang, Mei-Cheng Wang, Nonparametric Benefit–Risk Assessment Using Marker Process in the Presence of a Terminal Event, Journal of the American Statistical Association, 10.1080/01621459.2016.1180988, 112, 518, (826-836), (2017).
- Claire Williams, James D. Lewsey, Daniel F. Mackay, Andrew H. Briggs, Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling, Medical Decision Making, 10.1177/0272989X16670617, 37, 4, (427-439), (2016).
- Emilie Bogart, Anaïs Jouin, Hélène Béhal, Alain Duhamel, Thomas Filleron, Andrew Kramar, Analysis of survival adjusted for quality of life using the Q-TWiST function: Interface in R, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2015.11.005, 125, (79-87), (2016).
- Haomiao Jia, Erica I. Lubetkin, Impact of nine chronic conditions for US adults aged 65 years and older: an application of a hybrid estimator of quality-adjusted life years throughout remainder of lifetime, Quality of Life Research, 10.1007/s11136-016-1226-5, 25, 8, (1921-1929), (2016).
- John G Williams, M Fasih Alam, Laith Alrubaiy, Ian Arnott, Clare Clement, David Cohen, John N Gordon, A Barney Hawthorne, Mike Hilton, Hayley A Hutchings, Aida U Jawhari, Mirella Longo, John Mansfield, Jayne M Morgan, Frances Rapport, Anne C Seagrove, Shaji Sebastian, Ian Shaw, Simon P L Travis, Alan Watkins, Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial, The Lancet Gastroenterology & Hepatology, 10.1016/S2468-1253(16)30003-6, 1, 1, (15-24), (2016).
- Sebastian Hinde, David Epstein, Adrian Cook, Andrew Embleton, Timothy Perren, Mark Sculpher, The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial, Value in Health, 10.1016/j.jval.2016.01.013, 19, 4, (431-439), (2016).
- Sophie Marguet, Chafika Mazouni, Bram L.T. Ramaekers, Ariane Dunant, Ronald Kates, Volker R. Jacobs, Manuela A. Joore, Nadia Harbeck, Julia Bonastre, European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer, European Journal of Cancer, 10.1016/j.ejca.2016.05.013, 63, (168-179), (2016).
- Dianliang Deng, Estimating the cumulative mean function for history process with time‐dependent covariates and censoring mechanism, Statistics in Medicine, 10.1002/sim.6998, 35, 25, (4624-4636), (2016).
- Jianmin Wang, Guy Hechmati, Jun Dong, Gregory A. Maglinte, Beth Barber, Jean-Yves Douillard, Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer , Current Medical Research and Opinion, 10.1185/03007995.2015.1124075, 32, 3, (459-465), (2016).
- Shiqi Cui, Yueqin Zhao, Ram C. Tiwari, Bayesian Approach to Personalized Benefit-Risk Assessment, Statistics in Biopharmaceutical Research, 10.1080/19466315.2016.1193045, 8, 3, (316-324), (2016).
- Diane L Fairclough, Patient reported outcomes as endpoints in medical research, Statistical Methods in Medical Research, 10.1191/0962280204sm357ra, 13, 2, (115-138), (2016).
- L J Billingham, K R Abrams, Simultaneous analysis of quality of life and survival data, Statistical Methods in Medical Research, 10.1191/0962280202sm269ra, 11, 1, (25-48), (2016).
- A R Willan, D Y Lin, R J Cook, E B Chen, Using inverse-weighting in cost-effectiveness analysis with censored data, Statistical Methods in Medical Research, 10.1191/0962280202sm308ra, 11, 6, (539-551), (2016).
- Peter F Thall, Ethical issues in oncology biostatistics, Statistical Methods in Medical Research, 10.1191/0962280202sm301ra, 11, 5, (429-448), (2016).
- John G Williams, M Fasihul Alam, Laith Alrubaiy, Clare Clement, David Cohen, Michelle Grey, Mike Hilton, Hayley A Hutchings, Mirella Longo, Jayne M Morgan, Frances L Rapport, Anne C Seagrove, Alan Watkins, Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT), Health Technology Assessment, 10.3310/hta20440, 20, 44, (1-320), (2016).
- Laura M. Yee, Kwun Chuen Gary Chan, Nonparametric inference for the joint distribution of recurrent marked variables and recurrent survival time, Lifetime Data Analysis, 10.1007/s10985-015-9347-7, 23, 2, (207-222), (2015).
- C L Bowden, J Mintz, M Tohen, Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder, Molecular Psychiatry, 10.1038/mp.2015.21, 21, 2, (237-242), (2015).
- MA Hopkins, MA Goeree, Survival Analysis, Health Technology Assessment, 10.1201/b18285, (149-178), (2015).
- Mauricio Tohen, Clinical Trial Design of Maintenance Treatments in Bipolar Disorder, Clinical Trial Design Challenges in Mood Disorders, 10.1016/B978-0-12-405170-6.00001-4, (1-12), (2015).
- Amin Khademi, Denis R. Saure, Andrew J. Schaefer, Ronald S. Braithwaite, Mark S. Roberts, The Price of Nonabandonment: HIV in Resource-Limited Settings, Manufacturing & Service Operations Management, 10.1287/msom.2015.0545, 17, 4, (554-570), (2015).
- Laura M. Yee, Kwun Chuen Gary Chan, Nonparametric inference for time‐dependent incremental cost‐effectiveness ratios, Statistics in Medicine, 10.1002/sim.6594, 34, 30, (4057-4069), (2015).
- Christian Pagnoux, Thomas Quéméneur, Jacques Ninet, Elisabeth Diot, Xavier Kyndt, Benoît Wazières, Jean‐Luc Reny, Xavier Puéchal, Pierre‐Yves Berruyer, Olivier Lidove, Philippe Vanhille, Pascal Godmer, Olivier Fain, Daniel Blockmans, Boris Bienvenu, Florence Rollot, Séverine Aït el Ghaz‐Poignant, Alfred Mahr, Pascal Cohen, Luc Mouthon, Elodie Perrodeau, Philippe Ravaud, Loïc Guillevin, Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy, Arthritis & Rheumatology, 10.1002/art.39011, 67, 4, (1117-1127), (2015).
- Allison Perrin, Steven Sherman, Sumanta Pal, Andrew Chua, Magdaliz Gorritz, Zhimei Liu, Xufang Wang, Kenneth Culver, Roman Casciano, Louis P. Garrison, Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US, Journal of Medical Economics, 10.3111/13696998.2014.985789, 18, 3, (200-209), (2014).
- Wendy R. Tate, Grant H. Skrepnek, Quality‐adjusted time without symptoms or toxicity (Q‐TWiST): patient‐reported outcome or mathematical model? A systematic review in cancer, Psycho-Oncology, 10.1002/pon.3595, 24, 3, (253-261), (2014).
- Adin-Cristian Andrei, Kathleen L. Grady, Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach, Quality of Life Research, 10.1007/s11136-013-0608-1, 23, 5, (1411-1419), (2014).
- Carolyn M. Astley, John F. Beltrame, Christopher Zeitz, Matthew Worthley, Penelope Coates, Alistair Murray, Margaret Arstall, Hugh Grantham, Robert Dunn, Stephen Quinn, Philip E. Aylward, Derek P. Chew, Study design of embracing high-sensitivity troponin effectively: The value of more information: A randomized comparison, Contemporary Clinical Trials, 10.1016/j.cct.2014.08.012, 39, 2, (183-190), (2014).
- Hannah E. Carter, Diana Zannino, R. John Simes, Deborah J. Schofield, Kirsten Howard, John R. Zalcberg, Timothy J. Price, Niall C. Tebbutt, The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study, European Journal of Cancer, 10.1016/j.ejca.2013.09.028, 50, 3, (535-543), (2014).
- Michele Reni, Yin Wan, Caitlyn Solem, Scott Whiting, Xiang Ji, Marc Botteman, Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis, Journal of Medical Economics, 10.3111/13696998.2014.903122, 17, 5, (338-346), (2014).
- Diane L. Fairclough, Patricia A. Ganz, Quality of Life, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Manfred Olschewski, Quality of Life and Survival Analysis, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Richard Kay, References, Statistical Thinking for Non‐Statisticians in Drug Regulation, 10.1002/9781118470961, (331-338), (2014).
- Diane L. Fairclough, Patricia A. Ganz, Quality of Life, Methods and Applications of Statistics in Clinical Trials, 10.1002/9781118596333, (608-621), (2014).
- Jennifer G Gaultney, William K Redekop, Pieter Sonneveld, Carin A Uyl-de Groot, Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value, Expert Review of Anticancer Therapy, 10.1586/era.12.42, 12, 6, (839-854), (2014).
- Farzan Siddiqui, Andre A Konski, Benjamin Movsas, Quality-of-life concerns in lung cancer patients, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1586/erp.10.81, 10, 6, (667-676), (2014).
- AJ Martin, RJ Simes, Quality-adjusted survival as an end point in breast cancer trials, Clinical Investigation, 10.4155/cli.13.37, 3, 6, (545-555), (2013).
- J. Wang, Y. Li, Revisit Kaplan–Meier Estimator in Estimating QAL Survival Distributions, Journal of Statistical Theory and Practice, 10.1080/15598608.2013.790235, 7, 3, (496-504), (2013).
- Chee Lee, Val J Gebski, Alan S Coates, Anne-Sophie Veillard, Vernon Harvey, Martin HN Tattersall, Michael J Byrne, Brian Brigham, John Forbes, R Simes, Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone, SpringerPlus, 10.1186/2193-1801-2-391, 2, 1, (391), (2013).
- Kathleen A. Boyd, Andrew H. Briggs, Pierre Ducournau, Marlene Gyldmark, Frederic de Reydet, Jim Cassidy, Statistical Issues with Trial Data and Economic Modeling for Cost-Effectiveness Evaluation, Modern Clinical Trial Analysis, 10.1007/978-1-4614-4322-3, (149-166), (2013).
- B Sherrill, J Wang, S Kotapati, K Chin, Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma, British Journal of Cancer, 10.1038/bjc.2013.298, 109, 1, (8-13), (2013).
- Christy Chuang-Stein, Quantitative Risk/Benefit Assessment: Where Are We?, Proceedings of the Fourth Seattle Symposium in Biostatistics: Clinical Trials, 10.1007/978-1-4614-5245-4_8, (119-135), (2013).
- Huazhen Lin, Yi Li, Ming T. Tan, Estimating a unitary effect summary based on combined survival and quantitative outcomes, Computational Statistics & Data Analysis, 10.1016/j.csda.2013.03.028, 66, (129-139), (2013).
- Lu Wang, Andrea Rotnitzky, Xihong Lin, Randall E. Millikan, Peter F. Thall, Rejoinder, Journal of the American Statistical Association, 10.1080/01621459.2012.665198, 107, 498, (518-520), (2012).
- Roman Casciano, Maruit Chulikavit, Allison Perrin, Zhimei Liu, Xufang Wang, Louis P. Garrison, Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States, Journal of Medical Economics, 10.3111/13696998.2012.720319, 15, sup1, (55-64), (2012).
- Andrea Troxel, Carol Moinpour, John Crowley, Antje Hoering, Design and Analysis of Quality-of-Life Data, Handbook of Statistics in Clinical Oncology, Third Edition, 10.1201/b11800, (339-368), (2012).
- Mau-Roung Lin, Wen-Yu Yu, Shih-Chieh Wang, Examination of Assumptions in Using Time Tradeoff and Standard Gamble Utilities in Individuals With Spinal Cord Injury, Archives of Physical Medicine and Rehabilitation, 10.1016/j.apmr.2011.08.039, 93, 2, (245-252), (2012).
- Julio Lambea, Carmen Hinojo, Nuria Lainez, Martín Lázaro, Luís León, Ángel Rodríguez, Diego Soto de Prado, Emilio Esteban, Quality of life and supportive care for patients with metastatic renal cell carcinoma, Cancer and Metastasis Reviews, 10.1007/s10555-012-9357-9, 31, S1, (33-39), (2012).
- Gisela Tunes-da-Silva, Antonio Carlos Pedroso-de-Lima, Pranab Kumar Sen, Quality of Life Perspectives in Chronic Disease and Disorder Studies, Handbook of Statistics Volume 28, 10.1016/B978-0-44-451875-0.00016-6, (401-431), (2012).
- Yung-Jue Bang, Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer, Journal of Clinical Gastroenterology, 10.1097/MCG.0b013e3182557307, 46, 8, (637-648), (2012).
- Arthur S. Zbrozek, Gary Hudes, Donna Levy, Andrew Strahs, Anna Berkenblit, Robert De Marinis, Shreekant Parasuraman, Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma, PharmacoEconomics, 10.2165/11535290-000000000-00000, 28, 7, (577-584), (2012).
- Patricia K. Corey‐Lisle, Ronald Peck, Pralay Mukhopadhyay, Lucinda Orsini, Shima Safikhani, Jill A. Bell, Gabriel Hortobagyi, Henri Roche, Pierfranco Conte, Dennis A. Revicki, Q‐TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer, Cancer, 10.1002/cncr.26213, 118, 2, (461-468), (2011).
- Paul W. Armstrong, Cynthia M. Westerhout, Frans Van de Werf, Robert M. Califf, Robert C. Welsh, Robert G. Wilcox, Jeffrey A. Bakal, Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolytic–3 (ASSENT-3) trial, American Heart Journal, 10.1016/j.ahj.2010.12.026, 161, 5, (848-854), (2011).
- Evo Alemao, Srinivasan Rajagopalan, Shiyi Yang, Rafael E. Curiel, Joseph Purvis, Maiwenn J. Al, Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma, Journal of Medical Economics, 10.3111/13696998.2011.566296, 14, 2, (245-252), (2011).
- R.M. Sladek, T. Jones, P.A. Phillips, M. Luszcz, D. Rowett, S. Eckermann, R.J. Woodman, P. Frith, Health, economic, psychological and social impact of educating carers of patients with advanced pulmonary disease (protocol), Contemporary Clinical Trials, 10.1016/j.cct.2011.05.004, 32, 5, (717-723), (2011).
- J Wang, Z Zhao, B Barber, B Sherrill, M Peeters, J Wiezorek, A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer, British Journal of Cancer, 10.1038/bjc.2011.179, 104, 12, (1848-1853), (2011).
- Christoph Eimer, Holger Gerullis, Christoph Heuck, Thomas Otto, mTOR inhibition in advanced renal cell carcinoma, Anti-Cancer Drugs, 10.1097/CAD.0b013e3283407dde, 22, 1, (18-23), (2011).
- Martin R. Stockler, Vernon J. Harvey, Prudence A. Francis, Michael J. Byrne, Stephen P. Ackland, Bernie Fitzharris, Guy Van Hazel, Nicholas R.C. Wilcken, Peter S. Grimison, Anna K. Nowak, M. Corona Gainford, Akiko Fong, Lisa Paksec, Tatiana Sourjina, Diana Zannino, Val Gebski, R. John Simes, John F. Forbes, Alan S. Coates, Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer, Journal of Clinical Oncology, 10.1200/JCO.2010.33.9101, 29, 34, (4498-4504), (2011).
- Hong-Bin Fang, Jiantian Wang, Dianliang Deng, Man-Lai Tang, Estimating the mean of a mark variable under right censoring on the basis of a state function, Computational Statistics & Data Analysis, 10.1016/j.csda.2010.10.028, 55, 4, (1726-1735), (2011).
- Beth Sherrill, Bintu Sherif, Mayur M. Amonkar, Julie Maltzman, Lisa O’Rourke, Stephen Johnston, Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib, Current Medical Research and Opinion, 10.1185/03007995.2011.621209, 27, 12, (2245-2252), (2011).
- D.W.J. Dippel, J.D.F. Habbema, Decision analysis in the clinical neurosciences: a systematic review of the literature, European Journal of Neurology, 10.1111/j.1468-1331.1995.tb00170.x, 2, 6, (523-539), (2011).
- Biswabrata Pradhan, Anup Dewanji, Nonparametric estimator for the survival function of quality adjusted lifetime (QAL) in a three-state illness–death model, Journal of the Korean Statistical Society, 10.1016/j.jkss.2010.02.005, 39, 3, (315-324), (2010).
- Fei Gao, Joseph Wee, Hwee Bee Wong, David Machin, Quality-of-Life-Adjusted Survival Analysis of Concurrent Chemo Radiotherapy for Locally Advanced (Nonmetastatic) Nasopharyngeal Cancer, International Journal of Radiation Oncology*Biology*Physics, 10.1016/j.ijrobp.2009.07.1702, 78, 2, (454-460), (2010).
- A. Vergnenègre, C. Chouaïd, Aspects médico-économiques de la pneumologie, Revue des Maladies Respiratoires Actualités, 10.1016/S1877-1203(10)70049-5, 2, 2, (205-222), (2010).
- Biswabrata Pradhan, Anup Dewanji, Debasis Sengupta, Parametric Estimation of Quality Adjusted Lifetime (QAL) Distribution in Simple Illness-Death Model, Communications in Statistics - Theory and Methods, 10.1080/03610920802687777, 39, 1, (77-93), (2010).
- Yichuan Zhao, Hongkun Wang, Empirical likelihood inference for the regression model of mean quality‐adjusted lifetime with censored data, Canadian Journal of Statistics, 10.1002/cjs.5550360309, 36, 3, (463-478), (2010).
- Steven Schwartz, Jeffrey Richardson, Paul P. Glasziou, Quality‐adjusted life years: origins, measurements, applications, objections, Australian Journal of Public Health, 10.1111/j.1753-6405.1993.tb00149.x, 17, 3, (272-278), (2010).
- Philip M. Clarke, Alison J. Hayes, Paul G. Glasziou, Russell Scott, John Simes, Anthony C. Keech, Using the EQ-5D Index Score as a Predictor of Outcomes in Patients With Type 2 Diabetes, Medical Care, 10.1097/MLR.0b013e3181844855, 47, 1, (61-68), (2009).
- Biswabrata Pradhan, Anup Dewanji, On induced dependent censoring for quality adjusted lifetime (QAL) data in a simple illness–death model, Statistics & Probability Letters, 10.1016/j.spl.2009.07.010, 79, 20, (2170-2176), (2009).
- Chris Barker, The Mean, Median, and Confidence Intervals of the Kaplan-Meier Survival Estimate—Computations and Applications, The American Statistician, 10.1198/tast.2009.0015, 63, 1, (78-80), (2009).
- Hongkun Wang, Yichuan Zhao, A comparison of some confidence intervals for the mean quality-adjusted lifetime with censored data, Computational Statistics & Data Analysis, 10.1016/j.csda.2009.01.013, 53, 7, (2733-2739), (2009).
- Kaushal K. Mishra, Sujit K. Ghosh, Bayesian Regression Models for the Quality Adjusted Lifetime Data with Zero Time Duration Health States, Journal of Statistical Theory and Practice, 10.1080/15598608.2009.10411939, 3, 2, (477-487), (2009).
- W. Tawfick, S. Sultan, Does Topical Wound Oxygen (TWO2) Offer an Improved Outcome Over Conventional Compression Dressings (CCD) in the Management of Refractory Venous Ulcers (RVU)? A Parallel Observational Comparative Study, European Journal of Vascular and Endovascular Surgery, 10.1016/j.ejvs.2009.03.027, 38, 1, (125-132), (2009).
- Raymond W. Jang, Aurélie Le Maître, Keyue Ding, Tim Winton, Andrea Bezjak, Lesley Seymour, Frances A. Shepherd, Natasha B. Leighl, Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial, Journal of Clinical Oncology, 10.1200/JCO.2008.20.5815, 27, 26, (4268-4273), (2009).
- Biswabrata Pradhan, Anup Dewanji, Parametric estimation of quality adjusted lifetime (QAL) distribution in progressive illness–death model, Statistics in Medicine, 10.1002/sim.3556, 28, 15, (2012-2027), (2009).
- Diane L. Fairclough, Quality of Life, Cancer Investigation, and Clinical Practice, Cancer Investigation, 10.3109/07357909809011702, 16, 7, (478-484), (2009).
- See more




